ONCT - Oncternal: Solid Data In 2 Cancers With High Unmet Need June, 17 2021 01:59 PM Oncternal Therapeutics Inc. ONCT presented solid data in MCL and ES. There's potential for accelerated approval. The company has a history of diluting shares. For further details see: Oncternal: Solid Data In 2 Cancers With High Unmet Need